课题基金 / 基金详情

Mechanism for the delayed elimination of SN-38 in cancer patients with severe renal failure and optimal treatment strategy

Mechanism for the delayed elimination of SN-38 in cancer patients with severe renal failure and optimal treatment strategy
严重肾功能衰竭癌症患者SN-38延迟消除机制及最佳治疗策略
批准号:
23590198
负责人:
FUJITA Ken-ichi
金额:
$3.41万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2013

项目摘要

项目成果

FUJITA Ken-ichi的其他基金

相似基金

相关文献

中文摘要
翻译
我们首次证明,尿毒症毒素如CMPF在临床相关浓度下抑制人肝细胞中的SN-38摄取。OATP 1B 1是人肝细胞中SN-38饱和摄取的主要贡献者。尿毒症血浆可下调SLCO 1B 1基因的表达。尿毒症毒素对OATP 1B 1介导的SN-38摄取的抑制和SLCO 1B 1基因表达的下调可能是导致重度肾功能不全患者中观察到的SN-38消除延迟的部分机制。
英文摘要
We have shown for the first time that uremic toxins such as CMPF inhibit SN-38 uptake in human hepatocytes at clinically relevant concentrations. OATP1B1 is a major contributor to the saturable uptake of SN-38 in human hepatocytes. The gene expression of SLCO1B1 was down-regulated by uremic plasma. The inhibition by uremic toxins of OATP1B1-mediated SN-38 uptake and the down-regulated SLCO1B1 gene expressions may be part of the mechanisms causing the delay of SN-38 elimination observed in patients with severe renal dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Partial inhibition by uremic toxins of hepatic uptake of an active metabolites SN-38 of irinotecan in humans
尿毒症毒素部分抑制人体肝脏摄取伊立替康活性代谢物 SN-38
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Fujita K, Sugiura T, Nakamichi N, Akiyama Y, Sasaki Y, Kato Y]
通讯作者: Kato Y
Down-regulation by uremic plasma components of hepatic uptake transporter for SN-38 in humans
人类尿毒症血浆成分对 SN-38 的肝摄取转运蛋白的下调
DOI: --
发表时间: 2013
期刊:
影响因子: --
作者: [Fujita K, Nakamichi N, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y]
通讯作者: Kato Y
Involvement of OATP and inhibition by uremic toxins in hepatic uptake of an anticancer agent SN-38 in humans
OATP 和尿毒症毒素抑制参与人类抗癌剂 SN-38 的肝脏摄取
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Sugiura T, Fujita K, Okumura H, Umeda S, Nakamichi N, Sasaki Y, Kato Y]
通讯作者: Kato Y
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
基于药代动力学和药效学优化癌症化疗:从参加临床试验的患者到“现实世界”中的患者。
DOI: --
发表时间: 2014
期刊: Drug Metabolism and Pharmacokinetics
影响因子: 2.1
作者: [Ken, Y. Sasaki]
通讯作者: Y. Sasaki
16
    Efficient Hydrogen Production from Renewable Natural Organic Resources Under Mild Conditions
    • 批准号:
      26620153
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2014
    • 负责人:
      FUJITA Ken-ichi
    • 依托单位:
    Involvement of calcium signal in gene regulation related to drug exhaust
    • 批准号:
      25460128
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2013
    • 负责人:
      FUJITA Ken-ichi
    • 依托单位:
    Development of novel recyclable homogeneous metal complex catalysts
    Development of Oxidant-Free Oxidation of Alcohols Catalyzed by Group 9 Metal Complexes and their Application to Organic Synthesis
    • 批准号:
      19750075
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.36万
    • 财政年份:
      2007
    • 负责人:
      FUJITA Ken-ichi
    • 依托单位:
    海外基金